| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.02 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.15 | 0.03 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |